Cerebrospinal fluid biomarkers in neurodegenerative disorders

Written by Thalia T Robey & Peter K Panegyres

Neurodegenerative diseases represent a daunting challenge in clinical diagnosis and management. Biomarkers that might aid in the diagnosis of these devastating and globally important diseases are urgently sought and required. Here we describe the application and state of development of a range of cerebrospinal fluid biomarkers in common neurodegenerative disorders including Alzheimer’s disease, frontotemporal dementia and prion diseases. Alzheimer’s disease Cerebrospinal fluid (CSF) biomarkers and their use in neurodegenerative disorders represent an emerging area of research. The clinical use of CSF biomarkers for Alzheimer’s disease (AD) is better supported than for other neurodegenerative diseases. CSF biomarkers are useful as screening...

To view this content, please register now for access

It's completely free